0001437749-23-016769.txt : 20230718 0001437749-23-016769.hdr.sgml : 20230718 20230606171006 ACCESSION NUMBER: 0001437749-23-016769 CONFORMED SUBMISSION TYPE: CORRESP PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20230606 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Panbela Therapeutics, Inc. CENTRAL INDEX KEY: 0001029125 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 870543922 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: CORRESP BUSINESS ADDRESS: STREET 1: 712 VISTA BLVD #305 CITY: WACONIA STATE: MN ZIP: 55387 BUSINESS PHONE: 9524791196 MAIL ADDRESS: STREET 1: 712 VISTA BLVD #305 CITY: WACONIA STATE: MN ZIP: 55387 FORMER COMPANY: FORMER CONFORMED NAME: Sun BioPharma, Inc. DATE OF NAME CHANGE: 20150911 FORMER COMPANY: FORMER CONFORMED NAME: Cimarron Medical, Inc. DATE OF NAME CHANGE: 20150602 FORMER COMPANY: FORMER CONFORMED NAME: CIMARRON SOFTWARE INC DATE OF NAME CHANGE: 19961217 CORRESP 1 filename1.htm pbla20230606_corresp.htm

 

June 6, 2023

 

VIA EDGAR TRANSMISSION

 

Division of Corporation Finance

United States Securities and Exchange Commission

100 F Street, N.E.

Washington, D.C. 20549-6010

 

Attn:

Tim Buchmiller

 

 

Re:

Panbela Therapeutics, Inc.
   

Registration Statement on Form S-1 (Registration No. 333-271729)
   

Request for Acceleration of Effective Date

 

Ladies and gentlemen:

 

In accordance with Rule 461 under the Securities Act of 1933, as amended (the “Act”), Panbela Therapeutics, Inc. (the “Company”) hereby respectfully requests that the Securities and Exchange Commission take appropriate action to cause the Registration Statement on Form S-1 (File No. 333-271729) (the “Registration Statement”) to become effective on June 8, 2023, at 4:30 p.m., Eastern Time, or as soon as thereafter possible. The Company hereby acknowledges its responsibilities under the Act as they relate to the proposes public offering of the securities specified in the Registration Statement.

 

Please direct any questions or comments concerning this request to Joshua L. Colburn of Faegre Drinker Biddle & Reath LLP, counsel to the Company, at +1 (612) 766-8946.

 

[Signature Page Follows]

 

 
 

 

 

Very truly yours,
   
 

PANBELA THERAPEUTICS, INC.

     
 

By:

/s/ Susan Horvath
 

Name: 

Susan Horvath
 

Title:

Chief Financial Officer

 

 
 

 

Roth Capital Partners, LLC

888 San Clemente Drive, Suite 400

Newport Beach, CA 92660

 

June 6, 2023

 

 

VIA EDGAR CORRESPONDENCE

 

U.S. Securities and Exchange Commission

Division of Corporation Finance

100 F Street, N.E.
Washington, D.C. 20549

  

 

Re:         Panbela Therapeutics, Inc.
Registration Statement on Form S-1

File No. 333-271729

 

Ladies and Gentlemen:

 

Pursuant to Rule 461 of the General Rules and Regulations under the Securities Act of 1933, as amended (the “Act”), we, the placement agent, hereby request that the Securities and Exchange Commission (the “Commission”) take appropriate action to cause the above-referenced registration statement on Form S-1 (the “Registration Statement”) to become effective at 4:30 p.m., Eastern time, on Thursday, June 8, 2023, or as soon thereafter as practicable.

 

Pursuant to Rule 460 under the Act, we wish to advise you that we have distributed as many copies of the Preliminary Prospectus dated June 2, 2023 to agents, dealers, institutions and others as appears to be reasonable to secure adequate distribution of the preliminary prospectus.

 

The undersigned, as placement agent, has complied and will comply with Rule 15c2-8 under the Securities Exchange Act of 1934, as amended.

 

 

Very truly yours,

 

 

ROTH CAPITAL PARTNERS, LLC

 

 

By: /s/ Aaron M. Gurewitz                          
Aaron M. Gurewitz
Head of Equity Capital Markets

 

 

cc:

M. Ali Panjwani, Esq.
 

Pryor Cashman LLP